Altamira Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

 

• Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles
• Targeting safer and accessible mRNA vaccines

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines. Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics, in a simple, scalable and cost-efficient way.

Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform. Should the experiments prove successful, Univercells and Altamira intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.

https://www.globenewswire.com/news-release/2024/03/25/2851634/0/en/Altamira-Therapeutics-Announces-Collaboration-with-Univercells-Group-on-Nanoparticle-Delivered-mRNA-Vaccines.html